{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:55:00Z","timestamp":1791888900809,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001702","name":"AO foundation","doi-asserted-by":"publisher","award":["AOCMF 14-070"],"award-info":[{"award-number":["AOCMF 14-070"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001702","name":"AO foundation","doi-asserted-by":"publisher","award":["AOCMF 64-210"],"award-info":[{"award-number":["AOCMF 64-210"]}],"id":[{"id":"10.13039\/501100001702","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Friedrich-Baur","award":["(65\/09 and 71\/11)"],"award-info":[{"award-number":["(65\/09 and 71\/11)"]}]},{"name":"Curt-Bohnewand foundations"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jcms.2018.05.046","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:03:47Z","timestamp":1527811427000},"page":"1515-1525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-6046","authenticated-orcid":false,"given":"Suad","family":"Aljohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7220","authenticated-orcid":false,"given":"Robert","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Tr\u00f6ltzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ehrenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Kaeppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcms.2018.05.046_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.joms.2013.09.008","article-title":"Stage 0 osteonecrosis of the jaw in a patient on denosumab","volume":"72","author":"Aghaloo","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on denosumab","volume":"68","author":"Aghaloo","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jcms.2018.05.046_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/odi.12447","article-title":"Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis","volume":"22","author":"Bagan","year":"2016","journal-title":"Oral Dis"},{"key":"10.1016\/j.jcms.2018.05.046_bib6","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jcms.2018.05.046_bib7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2500a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2018.05.046_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.jcms.2018.05.046_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice","volume":"30","author":"de Molon","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2018.05.046_bib10","first-page":"e431","article-title":"Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (denosumab)\u2500review","volume":"21","author":"de Oliveira","year":"2016","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.jcms.2018.05.046_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/scd.12168","article-title":"Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach","volume":"36","author":"de Souza Povoa","year":"2016","journal-title":"Spec Care Dent"},{"key":"10.1016\/j.jcms.2018.05.046_bib12","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A\u00a0case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.14219\/jada.archive.2012.0323","article-title":"Denosumab-related osteonecrosis of the jaw","volume":"143","author":"Diz","year":"2012","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.jcms.2018.05.046_bib14","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib15","doi-asserted-by":"crossref","first-page":"1801676","DOI":"10.1155\/2016\/1801676","article-title":"Medication-related osteonecrosis of the jaws: considerations on a new antiresorptive therapy (denosumab) and treatment outcome after a 13-year experience","volume":"2016","author":"Favia","year":"2016","journal-title":"Int J Dent"},{"key":"10.1016\/j.jcms.2018.05.046_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jcms.2018.05.046_bib17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jcms.2018.05.046_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib20","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jcms.2018.05.046_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcms.2017.01.013","article-title":"Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ)","volume":"45","author":"Hoefert","year":"2017","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.joms.2011.02.104","article-title":"Osteonecrosis after administration of intravitreous bevacizumab","volume":"70","author":"Hopp","year":"2012","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2018.05.046_bib24","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcms.2018.05.046_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.oooo.2012.08.439","article-title":"The relationship of denosumab pharmacology and osteonecrosis of the jaws","volume":"114","author":"Malan","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jcms.2018.05.046_bib26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jcms.2018.05.046_bib28","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jcms.2018.05.046_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tripleo.2011.02.037","article-title":"Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center","volume":"112","author":"Nicolatou-Galitis","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jcms.2018.05.046_bib30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/adj.12217","article-title":"Denosumab and osteonecrosis of the jaws\u2500 the pharmacology, pathogenesis and a report of two cases","volume":"59","author":"O'Halloran","year":"2014","journal-title":"Aust Dent J"},{"key":"10.1016\/j.jcms.2018.05.046_bib31","first-page":"621","article-title":"Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis","volume":"46","author":"Ohga","year":"2015","journal-title":"Quintessence Int"},{"key":"10.1016\/j.jcms.2018.05.046_bib32","first-page":"3707","article-title":"Osteonecrosis of the jaw in patient with denosumab therapy","volume":"7","author":"Olate","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.jcms.2018.05.046_bib33","first-page":"3279","article-title":"Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"21","author":"Oster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jcms.2018.05.046_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcms.2013.05.038","article-title":"Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection","volume":"41","author":"Otto","year":"2013","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib35","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.joms.2009.07.079","article-title":"Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?","volume":"68","author":"Otto","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib36","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","article-title":"Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism","volume":"68","author":"Otto","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib37","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jcms.2016.05.018","article-title":"Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: a prospective cohort study","volume":"44","author":"Otto","year":"2016","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcms.2015.12.005","article-title":"Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: a series of thirteen patients","volume":"44","author":"Owosho","year":"2016","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib40","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jcms.2018.05.046_bib41","first-page":"5070187","article-title":"Denosumab related osteonecrosis of the jaw with spontaneous necrosis of the soft palate: report of a life threatening case","volume":"2016","author":"Qaisi","year":"2016","journal-title":"Case Rep Dent"},{"key":"10.1016\/j.jcms.2018.05.046_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.mayocp.2013.01.002","article-title":"Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy","volume":"88","author":"Rachner","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jcms.2018.05.046_bib44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bjoms.2014.01.021","article-title":"Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates","volume":"52","author":"Ristow","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","article-title":"Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)","volume":"43","author":"Ristow","year":"2015","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib46","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib48","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jcms.2018.05.046_bib49","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jcms.2018.05.046_bib50","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2018.05.046_bib51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jcms.2018.05.046_bib52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2018.05.046_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J\u00a0Evid Based Dent Pract"},{"key":"10.1016\/j.jcms.2018.05.046_bib54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.oooo.2015.07.017","article-title":"Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics","volume":"120","author":"You","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518218303330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518218303330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:39:21Z","timestamp":1760884761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518218303330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1010518218303330"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2018.05.046","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2018.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}